SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio announced NDA submission to the FDA for encaleret in ADH1,…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed May 12, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 12, 2026 at 07:30 ET

BridgeBio announced NDA submission to the FDA for encaleret in ADH1, supported by positive Phase 3 CALIBRATE data showing 76% of patients achieved target calcium levels vs 4% on standard of care (p<0.0001). If approved, encaleret would be the first approved therapy for ADH1, with a potential U.S. launch in early 2027 and an estimated diagnosed patient population of ~2,000 in the U.S.

  • NDA submitted to FDA for encaleret in autosomal dominant hypocalcemia type 1 (ADH1)
  • Phase 3 CALIBRATE trial met all primary and key secondary endpoints
  • 76% of encaleret patients achieved target serum and urine calcium vs 4% on conventional therapy (p<0.0001)
  • Encaleret restored endogenous PTH in 91.1% of patients vs 0% on standard of care at Week 24

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access